What is Galleri Test?

June 5, 2023

In a groundbreaking development, a blood test capable of detecting over 50 types of cancer has shown remarkable potential in a major trial conducted by the NHS. The test, known as the Galleri test, has demonstrated high accuracy rates and the ability to identify the original site of cancer in a significant percentage of positive cases.

Unveiling the Galleri Test

The Galleri test aims to revolutionize cancer detection by identifying treatable cancer at an early stage, thus offering a chance to save lives. In the trial, two-thirds (66.6%) of the cancers among the 5,000 participants with suspected symptoms were accurately identified through this blood test. Remarkably, in 85% of these positive cases, the Galleri test successfully pinpointed the original site of the cancer.

Enhancing Detection Capabilities

Traditional methods, such as scans and biopsies, subsequently diagnosed over 350 participants with cancer in the study. Among those who tested positive on the blood test, an impressive 75% were confirmed to have cancer through traditional methods. Even among those who initially tested negative, 2.5% were later diagnosed with cancer. Although not infallible, the Galleri test exhibited an 85% accuracy rate in detecting the source of cancer.

Targeting Specific Cancers

The Galleri test exhibits particular proficiency in detecting hard-to-spot cancers, including those affecting the head and neck, bowel, lung, pancreatic, and throat. By focusing on distinct changes in genetic code fragments released by different cancers, this innovative blood test presents an opportunity for early intervention and targeted treatment.

The Road Ahead

While the Galleri test shows immense promise, researchers from Oxford University emphasize that it remains a “work in progress.” However, if future studies yield positive results, the NHS plans to expand the test’s implementation. With initial results from testing the Galleri test on asymptomatic individuals expected next year, the NHS aims to extend its rollout to an additional one million people in 2024 and 2025.

« Previous PostNext Post »